You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《大行報告》野村微升石藥(01093.HK)目標價至11.27元 評級「買入」
阿思達克 11-24 10:37
野村發表研究報告指,維持石藥集團(01093.HK)「買入」評級,目標價由11.14元微升至11.27元。該行將集團2022及23財年的收入預測分別上調2%和5%,以反映2022財年強勁的原料藥銷售和2023財年的mRNA疫苗銷售貢獻。由於該行對疫苗的利潤率估計約爲50%,將其2022及2023財年的盈利預測分別上調0.4%和20.8%。 石藥第三季收入按年增長16%至79億元人民幣。該行認爲,由於維生素C和抗生素的利潤率較低,毛利率按年下降2.4個百分點至72.8%;研發費用按年增長16%至10.36億元人民幣,佔銷售額的13%;銷售費用按年增10%至27億元人民幣,佔銷售額的34.3%。因此,集團營業利潤率下降0.9個百分點至21.5%。純利按年增18%至15億元人民幣。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account